The Mesoblast Limited (ASX: MSB) share price has had a hard time of it lately. Its struggles seem to have been born from a 17% single-day plunge last month, from which the company – whose stock is also listed on the Nasdaq exchange under the ticker NASDAQ: MESO – hasn’t yet managed to recover.
In early morning trade on Wednesday, the Mesoblast share price is $1.36. That’s 20% lower than it was this time last month.
Let’s take a look at what’s been weighing on the biotechnology company recently.
What’s dragging the Mesoblast share price lower?
The Mesoblast share price has been feeling down since it announced a Swiss healthcare company dumped its product in mid-December.
Novartis terminated an agreement that could have seen Mesoblast’s remestemcel-L used to treat COVID-19-induced acute respiratory distress syndrome (ARDS).
As The Motley Fool noted at the time, the agreement’s cancellation saw around US$1.2 billion of Mesoblast’s potential earnings washed down the drain.
Of course, the agreement’s termination might have been expected by some.
It was put in place less than a month before Mesoblast released news its randomised control trial treating ventilator-dependent patients with ARDS due to COVID-19 was called off early after it became apparent it was unlikely to meet its primary endpoint.
The Mesoblast share price recovered some of its losses on 16 December. That’s when the company released positive news of a trial using remestemcel-L to treat chronic back pain.
Its shares gained 11% that day, but they didn’t manage to hold onto the boost.
In fact, the Mesoblast share price has already shed 3.55% year to date. It’s also 47% lower than it was this time last year.
On top that that, Mesoblast remains one of the most shorted stocks on the ASX. The Motley Fool’s most recent weekly breakdown of shorting found 9.1% of the company’s shares were in the hands of short sellers.
The post The Mesoblast (ASX:MSB) share price has tumbled 25% in a month. What’s going on? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast right now?
Before you consider Mesoblast, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- These are the 10 most shorted ASX shares
- These were the worst performing ASX 200 shares in December
- Why the Mesoblast (ASX:MSB) share price is rising 5% today
- Why Bega Cheese, Magnis, Mesoblast, and Neometals shares are pushing higher
- These are the 10 most shorted ASX shares
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3fdG0XA
Leave a Reply